Samsung Medical Center
samsunghospital.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
987
Active
141
Phase 3
64
Total enrollment
14,088,700
Pipeline matrix
Showing 40 of 54 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rebamipide 2% ophthalmic solution | — | — | — | — | — | 2 | |
| Diquafosol 3% ophthalmic solution | — | — | — | — | — | 2 | |
| Discontinuation of β-blocker | — | — | — | — | — | 1 | |
| Inhaled anesthetics | — | — | — | — | — | 1 | |
| Guideline directed statin therapy | — | — | — | — | — | 1 | |
| High intensity statin plus ezetimibe therapy | — | — | — | — | — | 1 | |
| Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin | — | — | — | — | — | 1 | |
| This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori. | — | — | — | — | — | 1 | |
| clopidogrel + aspirin | — | — | — | — | — | 1 | |
| Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day | — | — | — | — | — | 1 | |
| Rosuvastatin 20 mg orally once a day | — | — | — | — | — | 1 | |
| Propofol | — | — | — | — | 3 | ||
| SGLT2 inhibitor | — | — | — | — | 3 | ||
| P2Y12 antagonist monotherapy | — | — | — | — | 2 | ||
| Zastaprazan | — | — | — | — | — | 1 | |
| Proton Pump Inhibitors | — | — | — | — | — | 1 | |
| Vilanterol and Umeclidinium Bromide | — | — | — | — | — | 1 | |
| normal saline | — | — | — | — | 4 | ||
| pneumostem | — | — | — | — | 2 | ||
| Rivoceranib | — | — | — | — | — | 1 | |
| Tepotinib | — | — | — | — | — | 1 | |
| Osimertinib 80 MG | — | — | — | — | — | 1 | |
| Tisleizumab | — | — | — | — | — | 1 | |
| Glofitamab | — | — | — | — | — | 1 | |
| Selinexor | — | — | — | — | — | 1 | |
| Patritumab Deruxtecan | — | — | — | — | — | 1 | |
| Avelumab 10 mg/kg | — | — | — | — | — | 1 | |
| Belvarafenib | — | — | — | — | — | 1 | |
| Osimertinib 80Mg Tab | — | — | — | — | — | 1 | |
| Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab | — | — | — | — | — | 1 | |
| Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, | — | — | — | — | — | 1 | |
| concurrent chemotherapy | — | — | — | — | — | 1 | |
| Lazertinib | — | — | — | — | 3 | ||
| PNEUMOSTEM® | — | — | — | — | 2 | ||
| ET-STEM | — | — | — | — | — | 1 | |
| Etoposide | — | — | — | — | 11 | ||
| Cisplatin | — | — | — | — | 7 | ||
| Chemotherapy | — | — | — | — | 2 | ||
| fosaprepitant | — | — | — | — | — | 1 | |
| Insomnia medication | — | — | — | — | — | 1 |
14 more active programs hidden
Next readouts
- 2023-10-31
- 2025-07-05
- 2025-07-30
- 2025-08-31
- 2025-09
- 2025-12
- 2025-12
- 2025-12-30
- 2025-12-31
- 2025-12-31
Top conditions
- Stroke38
- Coronary Artery Disease29
- Breast Cancer24
- Gastric Cancer19
- Non-small Cell Lung Cancer13
- Benign Prostatic Hyperplasia11
- Hepatocellular Carcinoma11
- Ischemic Heart Disease10
Frequently asked questions about Samsung Medical Center
- How many clinical trials does Samsung Medical Center have on ClinicalTrials.gov?
- Samsung Medical Center is listed as the lead sponsor on 987 clinical trials in ClinicalTrials.gov, 141 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Samsung Medical Center's trials are in Phase 3?
- 64 of Samsung Medical Center's trials are in Phase 3, spread across 54 active drug programs.
- What therapeutic areas does Samsung Medical Center focus on?
- Samsung Medical Center's most-studied conditions on ClinicalTrials.gov are Stroke, Coronary Artery Disease, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer.
- When are Samsung Medical Center's next clinical trial readouts?
- Samsung Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Non-Selective Beta-Blockers on Outcomes in Cirrhosis Patients After Hospitalization: A Retrospective Cohort Using Target Trial Design”, expected around 2023-10-31.